What does the official instructions for gilitinib contain?

Gilitinib is an oral targeted drug mainly used to treat patients with acute myeloid leukemia (AML), especially those carrying FLT3 gene mutations. As an inhibitor targeting FLT3 receptor tyrosine kinase, giritinib has demonstrated significant efficacy and good safety in clinical application. Its official instruction manual details the indications, usage and dosage, pharmacological mechanism, adverse reactions, contraindications and precautions of the drug. The following is a comprehensive introduction to these key contents.

The indications of giritinib clearly indicate that the drug is mainly used to treat adult patients with acute myeloid leukemia who carry FLT3 gene mutations. FLT3mutation is a common molecular abnormality with poor prognosis in AML patients, and traditional treatments have limited effect. Giritinib improves the prognosis of patients by specifically inhibiting FLT3 tyrosine kinase activity, blocking signaling pathways, inhibiting the proliferation and survival of leukemia cells. The instructions also emphasize that before using giritinib, the patient's FLT3 mutation status should be confirmed through genetic testing to ensure accurate medication.

In the usage and dosage section, the official instructions recommend that the standard dose of gilitinib is once a day, usually 120mg, taken orally. The dosage should be adjusted according to the patient's specific condition and tolerance, and the doctor will make individual adjustments based on efficacy and side effects. It is generally recommended that the medication time has nothing to do with food, but in order to reduce gastrointestinal discomfort, patients can take it with food. In addition, blood, liver and kidney function, and electrocardiogram need to be monitored regularly during giritinib treatment to prevent drug-related side effects. The instructions also detail dosage adjustment recommendations due to drug interactions or abnormal liver and kidney function.

The pharmacological effects and adverse reactions of giritinib are mainly described in the instructions. The drug inhibits the activity of FLT3 receptor tyrosine kinase, blocks downstream signaling pathways, and reduces the proliferation and survival of leukemia cells. Common adverse reactions include bone marrow suppression (such as neutropenia, anemia, thrombocytopenia), abnormal liver function, gastrointestinal reactions (nausea, diarrhea), fatigue and fever. A small number of patients may develop serious adverse reactions such as QT interval prolongation, pancreatitis or hepatitis. Therefore, patients need to undergo close clinical monitoring during treatment. Once serious adverse reactions occur, the dose should be adjusted promptly or the medication should be suspended.

In addition, clear contraindications and precautions are listed in the instructions for gilitinib. Contraindications include those who are allergic to the components of this drug and those with severe liver and kidney dysfunction who cannot adjust the dose. The instructions also emphasize that the use of gilitinib in pregnant and lactating women requires weighing the pros and cons to avoid potential risks. During use, you should avoid taking drugs that may cause prolongation of the QT interval to reduce the risk of arrhythmia. Patients should inform their doctors of all their medication history and past medical history to prevent additional risks from drug interactions.

In summary, the official instructions for giritinib are comprehensive and cover core information such as the drug’s indications, usage and dosage, pharmacological mechanisms, adverse reactions, contraindications and precautions. It provides a scientific basis for clinicians to use giritinib rationally, and also helps patients correctly understand the efficacy and potential risks of the drug. By strictly following the instructions and guidelines, patients' medication safety can be ensured to the greatest extent, treatment effects can be improved, and the development of personalized precision medicine can be promoted.

Reference materials:https://www.xospata.com/